TY - JOUR
T1 - The Maudsley 3-item Visual Analogue Scale (M3VAS): validation of a scale measuring core symptoms of depression
AU - Moulton, Calum
AU - Strawbridge, Becci
AU - Tsapekos, Dimosthenis
AU - Oprea, Emanuella
AU - Carter, Ben
AU - Hayes, Chloe
AU - Cleare, Anthony
AU - Marwood, Lindsey
AU - Mantingh, Tim
AU - Young, Allan
N1 - Funding Information:
We are grateful to the patients who participated in the LQD and CRiB studies and individuals (researchers, service users, clinicians and students) involved in recruitment, data collection and management, design, oversight and analysis of these trials. We also thank the King's College Hospital Clinical Research Facility (CRF), the NIHR FAST-R service, King's College London Clinical Trials Unit, OPTIMA mood disorders service and SLaM Affective Disorders Service.
Funding Information:
This paper represents independent research part-funded by the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. This article presents independent research; the funders did not have a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The CRiB study was also funded by the NIHR Research for Patient Benefit (RfPB) program (ID PB-PG-0614–34,075) and LQD NIHR Health Technology Assessment (HTA) program (ID 14/222/02). C.D.M. is supported by an NIHR Academic Clinical Lectureship.
Funding Information:
A.H.Y. reports paid lectures and advisory board membership for the following companies with drugs used in affective and related disorders: AstraZeneca, Eli Lilly, Lundbeck, Sunovion, Servier, LivaNova, Allegan, Bionomics, Sumitomo, Dainippon Pharma and Janssen; consultancy to Johnson & Johnson and LivaNova; principal investigator on the Restore-Life VNS registry study funded by LivaNova and on ESKETINTRD3004 funded by Janssen. A.J.C. has in the last three years received honoraria for educational activities from Lundbeck and Janssen; honoraria for consulting from Allergan and Janssen; sponsorship for conference attendance from Janssen; and research grant support from Protexin Probiotics International Ltd. L.M. is currently an employee at COMPASS Pathways plc. This work is unrelated to COMPASS Pathways plc.
Publisher Copyright:
© 2020 Elsevier B.V.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/3/1
Y1 - 2021/3/1
N2 - Aims: Low mood and anhedonia are the core symptoms of major depressive disorder (MDD). However, there is no established visual analogue scale that measures pervasiveness of both symptoms. We aimed to validate the Maudsley 3-item Visual Analogue Scale (M3VAS) as a measure of core depressive symptoms and suicidality. Methods: This is a cross-sectional secondary analysis combining data from two randomised controlled trials covering a broad range of depression severity from euthymia to severe depression. We validated the M3VAS by testing: 1) latent construct domains using factor analysis; 2) internal consistency using Cronbach's alpha; and 3) convergent validity by correlating M3VAS scores against scores on the Quick Inventory of Depressive Symptomatology-16 item (QIDS-SR-16), which is validated for use in clinical trials. Results: Of 180 patients in the combined cohort, 177 (98.3%) provided complete data on the M3VAS and QIDS-SR-16. The mean (SD) age was 41.6 (13.0) years and 59.3% were female. Using factor analysis, one eigenvalue above 1 was produced (2.39) that explained 79.6% of the variance, indicating a one-factor model. Cronbach's alpha was 0.87, demonstrating good internal consistency. Total M3VAS scores correlated strongly (r = 0.72, p<0.001) with QIDS-SR-16 scores, indicating good convergent validity. Limitations: This was a cross-sectional study and was not validated against a clinician-rated assessment for depression. Conclusion: The M3VAS is a simple, valid instrument for the assessment of core depressive symptoms and suicidality across the depression spectrum. Future studies should test the longitudinal validity of the M3VAS in detecting changes in core depressive symptoms and suicidality over time.
AB - Aims: Low mood and anhedonia are the core symptoms of major depressive disorder (MDD). However, there is no established visual analogue scale that measures pervasiveness of both symptoms. We aimed to validate the Maudsley 3-item Visual Analogue Scale (M3VAS) as a measure of core depressive symptoms and suicidality. Methods: This is a cross-sectional secondary analysis combining data from two randomised controlled trials covering a broad range of depression severity from euthymia to severe depression. We validated the M3VAS by testing: 1) latent construct domains using factor analysis; 2) internal consistency using Cronbach's alpha; and 3) convergent validity by correlating M3VAS scores against scores on the Quick Inventory of Depressive Symptomatology-16 item (QIDS-SR-16), which is validated for use in clinical trials. Results: Of 180 patients in the combined cohort, 177 (98.3%) provided complete data on the M3VAS and QIDS-SR-16. The mean (SD) age was 41.6 (13.0) years and 59.3% were female. Using factor analysis, one eigenvalue above 1 was produced (2.39) that explained 79.6% of the variance, indicating a one-factor model. Cronbach's alpha was 0.87, demonstrating good internal consistency. Total M3VAS scores correlated strongly (r = 0.72, p<0.001) with QIDS-SR-16 scores, indicating good convergent validity. Limitations: This was a cross-sectional study and was not validated against a clinician-rated assessment for depression. Conclusion: The M3VAS is a simple, valid instrument for the assessment of core depressive symptoms and suicidality across the depression spectrum. Future studies should test the longitudinal validity of the M3VAS in detecting changes in core depressive symptoms and suicidality over time.
UR - http://www.scopus.com/inward/record.url?scp=85098886928&partnerID=8YFLogxK
U2 - 10.1016/j.jad.2020.12.185
DO - 10.1016/j.jad.2020.12.185
M3 - Article
SN - 0165-0327
VL - 282
SP - 280
EP - 283
JO - Journal of Affective Disorders
JF - Journal of Affective Disorders
ER -